The clinicopathological and prognostic significances of LATS1 expression in breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35142365/
doi: 10.14670/HH-18-433. Online ahead of print. 1 Department of Oncology and Experimental Center, The Affiliated Hospital of Chengde Medical University, Chengde, China. [email protected]. 2 Department of Oncology and Experimental Center,...
Conclusions: The downregulation of LATS1 expression plays a vital role in the carcinogenesis and progression of breast cancer. Thus, LATS1 loss was employed to indicate the aggressive behaviors and poor prognosis of breast cancer.
High serum exosomal long non‐coding RNA DANCR expression confers poor prognosis in patients with breast cancer
Source : https://onlinelibrary.wiley.com/doi/10.1002/jcla.24186
Linjun Yang , Corresponding Author Linjun Yang Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou City, Zhejiang Province, China Correspondence Linjun Yang, Department of Surgical Oncology, Taizhou Municipal Hospital, No.381...
Conclusion: Serum exosomal lncRNA DANCR may be a useful non-invasive biomarker for the clinical diagnosis and prognosis of BC.
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients - Breast Cancer Research and Treatment
Source : https://link.springer.com/article/10.1007/s10549-022-06525-3
Purpose Inferior overall response rate with abemaciclib plus endocrine therapy was observed in patients with hormone receptor-positive/HER2-negative advanced breast cancer (BC) and BMI ≥ 25. We assessed the impact of baseline BMI...
Conclusion: BMI categorized by the threshold of 25 did not significantly impact KI67% changes or clinical and radiological response. Although limited by the small sample size, these results are reassuring that the combination of abemaciclib plus anastrazole appears to be active in the early setting regardless of baseline BMI.
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35084948/
1 Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. 2 Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD....
Conclusion: The approval of abemaciclib in adjuvant EBC was limited to patients with high risk of recurrence and Ki-67 ≥ 20%, given their favorable benefit:risk with a statistically significant IDFS advantage and no observed detriment on survival.
In Brief: Abemaciclib (Verzenio) for Early Breast Cancer | The Medical Letter, Inc.
Source : https://secure.medicalletter.org/w1639c
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib ( Verzenio - Lilly), which was approved by the FDA in 2017 for treatment of hormone receptor (HR)-positive, human epidermal growth factor...
Conclusion: Addition of the oral CDK 4/6 inhibitor abemaciclib (Verzenio) to adjuvant endocrine therapy improved invasive disease-free survival at 3 years in women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer at high risk of recurrence. No data are available on the durability of this effect beyond 3...